These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular mechanisms of transformation by the BCR-ABL oncogene. Sattler M; Griffin JD Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368 [TBL] [Abstract][Full Text] [Related]
4. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Melo JV; Deininger MW Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392 [TBL] [Abstract][Full Text] [Related]
5. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]. Etienne G; Mahon FX Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816 [TBL] [Abstract][Full Text] [Related]
6. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544 [TBL] [Abstract][Full Text] [Related]
7. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells. Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053 [TBL] [Abstract][Full Text] [Related]
8. Modeling Philadelphia chromosome positive leukemias. Wong S; Witte ON Oncogene; 2001 Sep; 20(40):5644-59. PubMed ID: 11607816 [TBL] [Abstract][Full Text] [Related]
9. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Ren SY; Xue F; Feng J; Skorski T Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533 [TBL] [Abstract][Full Text] [Related]
12. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294 [TBL] [Abstract][Full Text] [Related]
13. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia. Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725 [TBL] [Abstract][Full Text] [Related]
14. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides]. Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009 [TBL] [Abstract][Full Text] [Related]
15. Important therapeutic targets in chronic myelogenous leukemia. Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816 [TBL] [Abstract][Full Text] [Related]
16. Physiological signals and oncogenesis mediated through Crk family adapter proteins. Feller SM; Posern G; Voss J; Kardinal C; Sakkab D; Zheng J; Knudsen BS J Cell Physiol; 1998 Dec; 177(4):535-52. PubMed ID: 10092207 [TBL] [Abstract][Full Text] [Related]
17. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826 [TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Gross AW; Ren R Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343 [TBL] [Abstract][Full Text] [Related]
20. Abl: the prototype of oncogenic fusion proteins. Saglio G; Cilloni D Cell Mol Life Sci; 2004 Dec; 61(23):2897-911. PubMed ID: 15583852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]